Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Humacyte, Inc. (HUMA : NSDQ)

• Company Description    Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C. Number of Employees: 184

• Price / Volume Information    Yesterday's Closing Price: $1.05 Daily Weekly Monthly 20 Day Moving Average: 6,593,060 shares Shares Outstanding: 222.02 (millions) Market Capitalization: $233.12 (millions) Beta: 2.31 52 Week High: $2.93 52 Week Low: $0.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 48.28% 41.04% 12 Week -14.63% -21.08% Year To Date 9.32% -2.37%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2525 EAST NORTH CAROLINA HIGHWAY 54 - DURHAM,NC 27713 USA ph: 919-313-9633 fax: - investors@humacyte.com http://www.humacyte.com

• General Corporate Information    Officers Laura E. Niklason - President and Chief Executive Officer Dale A. Sander - Chief Financial Officer Kathleen Sebelius - Director John Bamforth - Director Emery N. Brown - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 44486Q103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/10/26 Share - Related Items Shares Outstanding: 222.02 Most Recent Split Date: (:1) Beta: 2.31 Market Capitalization: $233.12 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.32 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 20.06 Price/Cash Flow: - Price / Sales: 115.63 EPS Growth vs. Year Ago Period: 10.00% vs. Previous Quarter: 30.77% Sales Growth vs. Year Ago Period: -4.26% vs. Previous Quarter: 6.00% ROE 03/31/26 - -2,914.18 12/31/25 - -990.48 09/30/25 - - ROA 03/31/26 - -89.45 12/31/25 - -74.79 09/30/25 - -68.85 Current Ratio 03/31/26 - 3.93 12/31/25 - 3.69 09/30/25 - 1.62 Quick Ratio 03/31/26 - 3.32 12/31/25 - 2.95 09/30/25 - 0.90 Operating Margin 03/31/26 - -5,071.63 12/31/25 - -4,672.08 09/30/25 - - Net Margin 03/31/26 - -4,836.06 12/31/25 - -1,998.87 09/30/25 - - Pre-Tax Margin 03/31/26 - -4,840.82 12/31/25 - -2,003.58 09/30/25 - -2,353.22 Book Value 03/31/26 - 0.05 12/31/25 - 0.02 09/30/25 - -0.03 Inventory Turnover 03/31/26 - 0.88 12/31/25 - 0.76 09/30/25 - 0.07 Debt-to-Equity 03/31/26 - 5.46 12/31/25 - 20.08 09/30/25 - - Debt-to-Capital 03/31/26 - 84.52 12/31/25 - 95.25 09/30/25 - -

Powered by Zacks Investment Research ©